At the IGF2/H19 locus, aberrant methylation at DMRs that regulate the expression of IGF2 have been associated with IGF2 deregulation in many cancers, including colorectal, pancreatic and ovarian cancers and Wilms’ tumors [11, 13]. This evidence concerns the gene IGF2 and ovarian cancer.